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ABSTRACT (193; max 200) 
 
Clinical risk calculators are now widely available but have generally been implemented in a static 
and one-size-fits-all fashion. The objective of this study was to challenge these notions and show 
via a case study concerning risk-based screening for prostate cancer how calculators can be 
dynamically and locally tailored to improve on-site patient accuracy. Yearly data from five 
international prostate biopsy cohorts (3 in the US, 1 in Austria, 1 in England) were used to 
compare 6 methods for annual risk prediction: static use of the online US-developed Prostate 
Cancer Prevention Trial Risk Calculator (PCPTRC); recalibration of the PCPTRC; revision of the 
PCPTRC; building a new model each year using logistic regression, Bayesian prior-to-posterior 
updating, or random forests. All methods performed similarly with respect to discrimination, 
except for random forests, which were worse. All methods except for random forests greatly 
improved calibration over the static PCPTRC in all cohorts except for Austria, where the 
PCPTRC had the best calibration followed closely by recalibration. The case study shows that a 
simple annual recalibration of a general online risk tool for prostate cancer can improve its 
accuracy with respect to the local patient practice at hand. 
Keywords: prediction, discrimination, calibration, prostate cancer, logistic regression, revision 
Running title: Dynamic tailored risk prediction 
Text (3758, max 4000) 
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1. INTRODUCTION 
Clinical risk prediction tools are now widely available on the internet and provide a 
valuable decision-aid to doctors and patients regarding treatment choices. There are currently 
hundreds of clinical risk prediction tools available online, with objectives ranging from the 
prediction of onset of disease for use in screening to prognosis of outcomes following treatment 
for disease [1-3]. Interestingly, despite the recent interest in personalized approaches to medicine, 
the big data daily flowing into clinical practices, and changes in patient populations and clinical 
practice over time, these risk calculators have generally remained static and applied in a one-size-
fits-all fashion. For instance, 2013 US national guidelines for the prevention of cardiovascular 
diseases prescribed statins for persons with elevated risk based on a global score that was 
developed using a pooled cohort of patients monitored from the late 1980s to the early 2000s [4]. 
Subsequent validations on five external cohorts showed that the recommended risk score would 
greatly overestimate actual risk on contemporary populations, with up to 40 to 50% of the 
millions classified as high-risk in fact over-prescribed [5]. The widespread availability of 
electronic medical data raises the possibility that such models could instead evolve over time, 
automatically changing in tandem with evolving global clinical practice patterns [6]. Within 
individual hospitals, the ability to capitalize electronic medical record (EMR) data would 
additionally permit tailoring of a global risk tool to the hospital-specific patient population at 
hand, for example, allowing a different dynamic evolution of predictions for high-risk clinically 
referred versus healthy screening institutions. 
As the case study to be investigated in this article, the Prostate Cancer Prevention Trial 
Risk Calculator (PCPTRC) is a static risk tool that predicts the likelihood of detecting prostate 
cancer if a prostate biopsy were to be performed. It uses as inputs the commonly collected 
clinical risk factors: prostate-specific antigen (PSA), digital rectal exam (DRE), age, race, family 
history of prostate cancer, and prior biopsy history [3]. The model it is based on was developed 
using prostate biopsy data from participants on the placebo arm of a very unique prostate cancer 
prevention trial, the PCPT [7]. The PCPT provided the only patient population ever to be free of 
selection bias because at the end of seven years on the study all participants were requested to 
undergo prostate biopsy even if they lacked a clinical indication for biopsy (n = 5519) [8]. The 
posting of the calculator online in 2006 facilitated subsequent external validation on a range of 
cohorts that differed both in terms of patient composition and date of collection [9-21]. The latter 
was important since a shift in prostate biopsy practice occurred after the PCPT was completed: 
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the number of sampled tissue cores on biopsy increased from 6 cores (3 on each side) in the 
PCPT to the now contemporary practice of 12 cores (6 on each side). It has been documented that 
a greater number of biopsy cores retrieved at biopsy increases the chance of detection of prostate 
cancer [22]. 
 Statistical approaches to updating an existing risk prediction tool have been proposed, 
ranging from simple adjustment of the intercept of a model to re-estimation of multiple 
coefficients in the original model [23]. One-time updating approaches have been implemented in 
a variety of clinical settings, resulting in improved diagnostic or prognostic performance [24-29]. 
The need for continual temporal recalibration of a risk tool has been emphasized [30, 31], along 
with the concept of transfer learning from similar hospitals when sample sizes at individual 
institutions are low [32].  
In an era where patient data are housed electronically, risk prediction tools could and 
should be automatically updated with local data as soon as such data arrive. The objective of this 
study was to challenge the ubiquitous notion of static universal risk prediction and show via a 
case study how prediction can easily be adapted to the patient data on-site, and thus improve the 
accuracy of prediction for local patients. 
 
2. METHODS 
 
2.1. Participants and biopsy results 
Five international cohorts from the Prostate Biopsy Collaborative Group (PBCG) were 
used to compare various methods for developing an institution-specific risk calculator. These 
have been previously described [21]. Three screening cohorts, the San Antonio Center of 
Biomarkers of Risk for Prostate Cancer study (SABOR), Texas, U.S., ProtecT, UK, and Tyrol, 
Austria followed primarily a 10-core biopsy scheme. Two clinical cohorts from the U.S., 
Cleveland Clinic, Ohio and the Durham VA, North Carolina, comprised patients referred for 
clinical symptoms. Those three cohorts used mixed biopsy schemes, but primarily 10- to 14-
cores. Not all cohorts had all of the PCPTRC risk factors available; only those risk factors that 
were missing in less than 15% of the cases were used in the analysis. Biopsy records with 
associated PSA values higher than 50 ng/ml or with unknown Gleason grade were excluded. If 
cohorts had only few biopsies in the beginning and ending years, those years were aggregated 
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into the first and last year. The number of biopsies per year in the resulting data set ranged from 
73 (Durham) to 1106 (ProtecT).   
 
2.2. PCPTRC 
A modification of version 2.0 of the PCPTRC was used for the methods that tailored an 
existing risk tool [33]. While PCPTRC 2.0 provides separate estimates of the risks of low- versus 
high-grade prostate cancer, for this study a logistic regression of any prostate cancer was 
performed using the same dataset and the same covariates as the PCPTRC model: PSA, age, 
DRE, first-degree family history of prostate cancer, race (African American versus not) and 
history of a prior biopsy. When a risk factor was missing in more than 15% of biopsies in a 
cohort, it was not used in the analysis. This was the case for three of the binary covariates: 
African American race, prior biopsy and family history. Eight separate logistic regressions were 
run for each possible combination of missing values from these three variables and the 
corresponding model used for the cohort. The PCPTRC logistic regression models are given in 
Table 1 of the Supplementary Appendix. 
 
2.3. Validation sets and metrics 
The different statistical methods for annually updating a risk tool were compared using 
each consecutive year, starting with year 2, as the validation set, and all past years as a training 
set. In this manner the training set grew cumulatively in size with each year and the validation set 
changed each year. To compare methods in absence of a fluctuating validation set, the process 
was repeated using a fixed validation set consisting of the biopsies in the last three years of each 
cohort. The methods were compared in terms of discrimination and calibration. Discrimination 
was measured using the area-underneath-the-receiver-operating-characteristic-curve (AUC), 
which equals the probability that for a randomly chosen cancer case/control pair, the case has a 
higher predicted risk of cancer. AUCs vary from 50% (chance discrimination) to 100% (perfect 
discrimination), with higher values indicating better discrimination. Ninety-five percent 
confidence intervals (95% CI) for AUCs were calculated using non-parametric U-statistics as 
commonly implemented in statistical packages. Calibration was measured via the Hosmer-
Lemeshow statistic (HLS), which provides a single summary of the commonly used calibration 
plots. For each method of estimating risk, patients in the validation set were grouped into ten 
decile groups according to estimated risk: patients with the lowest 10th percentile of risks, risks in 
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the 10th to 20th percentile and so on up to patients with the highest 10th percentiles of risks. The 
observed rate of prostate cancer in each of the decile groups was computed (Og) and compared to 
the mean of the ng estimated risks in each decile group (Eg). The HLS equals the sum 
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, with larger values indicating poorer fit; 95% CIs for the HLS were 
computed using the approximation that the HLS follows a chi-square distribution with degrees of 
freedom equal to 8. 
 
2.4. Statistical methods 
Details of the individual methods follow. 
2.4.1. PCPTRC: 
This method performed no model building or augmentation and thus tests the value of a static 
model. For each individual in the training set the PCPTRC score was computed, allowing for 
missing values for some of the variables; see Supplementary Appendix, Table 1. 
2.4.2. Recalibration: 
This method performed a logistic regression on the training set using the PCPTRC linear 
predictor iPCPTRCiPCPTRC Xpred ,  as the only variable. The intercept and slope of the resulting 
linear predictor iPCPTRCupdateupdateiupdate predlp ,,    indicated how well the PCPTRC was 
calibrated to the training sample. An intercept of 0 and a slope of 1 corresponded to perfect 
calibration. The risk of prostate cancer in the test set was )}.exp(1/{1 ,iupdatelp  
2.4.3. Logistic regression: 
For this method a new logistic regression model was built using the training data and all 
PCPTRC risk factors age, race, PSA, DRE, family history, and prior biopsy history that were 
available in the training set (a “clean-slate” approach). 
Revision: In this method, not only the PCPTRC risk factors, but also the linear predictor of the 
PCPTRC was allowed to enter the logistic regression as a potential variable [23]. Model selection 
was performed using the stepwise Bayesian Information Criterion (BIC) to arrive at a logistic 
regression model with linear predictor ,iupdateupdate X  where Xi is a vector of predictors that 
contains iPCPTRCpred , and any other available PCPTRC risk factors. Stepwise regression was 
initiated separately with an intercept only model and with the model including all possible 
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variables. The model with lower BIC was selected for estimation of the risk of prostate cancer in 
the test set. 
2.4.4. Bayesian method: 
This approach was based on a logistic regression model assumed for the training data to form the 
data likelihood, and with a prior () for the vector of log odds ratios. The set of participants and 
variables were reduced so that all patients had all variables measured and the models could be fit 
using Markov Chain Monte Carlo (MCMC), which is implemented as part of the MCMCpack 
package in the R statistical software. The prior for  for each year was assumed to be multivariate 
normal. The prior mean was set to be the PCPTRC estimated coefficients. The prior variance 
matrix was set to be the estimated variance-covariance matrix of log odds ratios from the 
PCPTRC multiplied by the sample size of PCPTRC to dilute the information and yield a unit-
information prior [34]. 
2.4.5. Random forests: 
Random forests are a combination of many “trees”, where each regression tree starts with a root 
node containing the most influential covariate, finds the optimal cut point split on that covariate, 
and continues splitting subsequent branches by other covariates [35]. Trees are built from random 
bootstrap samples from the data set. We used the R package randomForest which implements the 
Breiman algorithm, using the default settings, including 500 trees. All available PCPTRC risk 
factors were allowed for the building of individual trees. We investigated an option whereby the 
PCPTRC linear predictor was also allowed, making this method a form of non-parametric 
revision. However, this turned out not to perform well due to the high correlation between the 
PCPTRC linear predictor and PSA, and the PCPTRC predictor was subsequently not allowed for 
inclusion. For prediction of cancer for a new individual, the percent of trees classifying the 
individual as a cancer case was used. 
 
3. RESULTS 
 
The five PBCG cohorts collected between 898 (SABOR) and 7260 (ProtecT) biopsies in 
the years 1994-2010 (Table 1). The two clinically referred cohorts, Cleveland Clinic and Durham 
VA, showed higher cancer rates, 39% and 46% respectively, than the three other, primarily 
screening, cohorts (27%-35%) (Figure 1). As expected, the PSA values were also higher in those 
two cohorts. Some biopsies in SABOR and almost half of the biopsies in Durham had missing 
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DRE. ProtecT did not collect DRE results at all. Family history was not present for Durham and 
Tyrol and the other three cohorts had missing values in 15%-40% of the cases. In the Austrian 
cohort, no information was available on the ethnicity but participants can be assumed to be 
primarily of Caucasian origin. Compared to the other cohorts, Durham VA had a remarkable 
representation of patients with African American origin (44%). In 20% of the cases patients had 
more than one biopsy. This fact was accounted for by the introduction of the risk factor prior 
biopsy. The data collection spanned timeframes between 8 years in ProtecT and 16 years in 
Durham VA. The yearly number of biopsies ranged from 73 to 1106.
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Table 1. Biopsy characteristics from the five PBCG cohorts. Prostate specific antigen (PSA) measured in ng/ml. Risk factors used in the 
models for each cohort (≤ 15% missing); SABOR & Cleveland Clinic: PSA, age, DRE, race, prior biopsy; ProtecT: PSA, age, family 
history, race; Tyrol: PSA, age, prior biopsy, DRE; Durham VA: PSA, age, race, prior biopsy. 
 SABOR Cleveland Clinic ProtecT Tyrol Durham VA 
 N = 898 N = 3257 N = 7260 N = 4749 N = 2185 
Age median (range) 64 (36, 89) 64 (50, 75) 63 (50, 72) 62 (50, 75) 64 (50, 75) 
PSA* median (range) 3.2 (0.1, 49.8) 5.7 (0.2, 49.9) 4.3 (3.0, 49.7) 4.0 (0.2, 49.6) 5.1 (0.1, 49.5) 
DRE result      
Normal 603 (67%) 3057 (94%) 0 (0%) 4392 (92%) 876 (40%) 
Abnormal 234 (26%) 200 (6%) 0 (0%) 357 (8%) 251 (11%) 
Unknown 61 (7%) 0 (0%) 7260 (100%) 0 (0%) 1058 (48%) 
Family history - - - - - 
No 244 (27%) 1679 (52%) 5692 (78%) 0 (0%) 0 (0%) 
Yes 295 (33%) 371 (11%) 453 (6%) 0 (0%) 0 (0%) 
Unknown 359 (40%) 1207 (37%) 1115 (15%) 4749 (100%) 2185 (100%) 
African origin      
No 794 (88%) 2799 (86%) 6878 (95%) 0 (0%) 1110 (51%) 
Yes 104 (12%) 412 (13%) 31 (0%) 0 (0%) 963 (44%) 
Unknown 0 (0%) 46 (1%) 351 (5%) 4749 (100%) 112 (5%) 
Prior biopsy      
Yes 305 (34%) 1089 (33%) 0 (0%) 1417 (30%) 548 (25%) 
No 593 (66%) 2168 (67%) 7260 (100%) 3332 (70%) 1637 (75%) 
N cancer cases (%) 285 (32%) 1265 (39%) 2507 (35%) 1281 (27%) 963 (44%) 
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Figure 1. Yearly cancer rates for the five PBCG cohorts. 
 
The six methods for dynamically updating a risk calculator were applied cumulatively to 
all years past in the cohort as a training set, with AUCs and HLSs evaluated on the next year as 
validation set. There were some large differences in validation performance for any given 
method. Focusing first on discrimination (Figure 2), the AUCs of methods evaluated on the 
SABOR data oscillated by up to 10 points across validation years and were almost at random 
performance (50%) in some years. Our expectation was that the prediction model would become 
more accurately trained to the cohort and the AUC would increase each year, but this was not the 
case for most of the cohorts. The logistic regression and the Bayesian updating exhibited almost 
identical performance throughout the cohorts. The AUCs of the revision method were 
comparable to the logistic regression method and the Bayesian approach, outperforming those in 
some years while not in others. Random forests were the worst performer in most cohorts, as they 
were consistently over-fitting the training data. Varying the tuning parameters did not help (data 
not shown). The static PCPTRC lagged behind the other 3 methods, all of which tailor to the 
institution, but was not statistically significantly inferior at the 95% level. The AUCs of the static 
PCPTRC and the recalibration were identical because recalibration is a monotonic transformation 
of the risk predictions. Differences in AUCs across cohorts were larger than differences among 
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methods within any single cohort. The overall performance of all methods was worst on 
Cleveland Clinic and best on the Durham VA cohort. 
 
Figure 2. AUCs using all past data as training and the next year as the validation year (x-axis). 
Higher values indicate better discrimination between cancer cases and control. The recalibration 
method gave identical results to the PCPTRC method. 
 
 
 
 In terms of calibration measured by the HLS, the random forest method performed so 
poorly that its values fell off the cohort graphs in Figure 3. The PCPTRC also performed 
statistically worse for the Cleveland Clinic, ProtecT and Durham VA cohorts. The PCPTRC 
performed better than the tailored approaches (logistic regression, Bayesian and revision) for 
some specific years in the SABOR cohort. In the early years of Tyrol, the static PCPTRC even 
outperformed recalibration. Typically these were the years where the cancer prevalence 
dramatically changed; see Figure 1. The tailored methods performed substantially worse after the 
abrupt change but adapted quickly so that performance was back to normal afterwards. By 
measuring calibration, closeness of expected to observed risks, on a squared loss scale rather than 
discrimination on a rank-based scale, the HLS was more sensitive for detecting changes in 
prediction that arise from sharp changes in prevalence or other characteristics.  
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Figure 3. Hosmer-Lemeshow test statistics using all past data as training and the next year as the 
validation year (x-axis). Lower values indicate better fit, closer agreement between observed and 
predicted risks. Random forests are omitted since their values were so high as to fall off the 
graph. 
 
When fixed validation sets comprising the last 3 years were considered, the AUC 
increased with size of the training set for most cohorts, but the gain in AUC was small 
(Supplementary Appendix Figure 1). Revision, Bayesian and logistic regression performed 
equally well and consistently outperformed the static PCPTRC. In terms of calibration measured 
by the HLS, the static PCPTRC performed substantially worse than all other methods in the 
Cleveland Clinic, ProtecT and Durham VA cohorts (Supplementary Appendix Figure 2). HLS 
decreased for increasing size of the training set in the SABOR, Tyrol and Durham VA cohorts. In 
most cohorts, the recalibration method performed best. 
 
4. DISCUSSION 
 
In this report we have investigated alternative approaches for solving two problems facing 
contemporary clinical risk tools at once: the need for such tools to evolve over time to adapt to 
changes in clinical practice patterns, and the need for such tools to be tailored to accommodate 
local differences in patient-populations. What we have observed is that compared to static use of 
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a global prediction model for prostate cancer prediction, recalibration often improved calibration 
but had little impact on discrimination both in terms of temporal evaluation within an institution 
as well as across different institutions. 
 A large number of prior studies have evaluated the advantages of one-time revisions to 
update long-standing clinical models for new patients at the same institution or network of 
institutions. To give a few examples, in the context of predicting the risk of postoperative pain, 
the recalibration approach significantly improved calibration beyond that obtained by more 
complicated revision methods, but also had no effect on discrimination, as found here [24]. 
Update of a static coronary artery disease model in a contemporary network of 14 institutions 
increased calibration and maintained discrimination [26]. A one-time temporal recalibration of a 
mortality model following colorectal surgery improved calibration [28]. Recalibration of a 
pediatric mortality tool enhanced calibration in subgroups, which diminished discrimination [29]. 
Discrimination in all of these studies was measured by the AUC. Based on ranks of observations, 
the AUC has been notoriously proven to be difficult to budge [36]. The failure of the AUC to 
increase over time in all cohorts as training data accumulated over the years could be that the 
current risk factors collected for prostate cancer have reached their discrimination potential; it has 
often been noted that new markers are needed to substantially improve current risk prediction 
tools for prostate cancer [37]. 
 There have been up to recently relatively fewer investigations of repeated temporal 
updates to existing clinical prediction models. Temporal quality control charts were used to 
monitor an intensive care unit score to monitor quality of care, with recalibration instigated when 
control measures exceeded bounds, and later extended to classification trees [30, 31]. This hinges 
on an interesting aspect not covered in this report – of diagnostic measures for assessing and only 
implementing recalibration when it is really needed. For a risk score predicting the mortality from 
cardiac surgery, repeated updates were performed to overcome the issue of calibration drift [38, 
39]. Changes in the coefficients of the risk model were monitored for different temporal updating 
schemes, but performance measures for discrimination and calibration were not investigated. 
Recently in the informatics field approaches to transfer learning for adapting risk tools from one 
hospital to another have developed [32, 40]. These rely on global maximization of an objective 
function that sums over individual hospitals, allowing individual hospitals to collect different 
predictors. These were developed for the case of rare diseases, where the incidence is so low as to 
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demand synthesis of information across multiple hospitals, as well as to where no static risk 
calculator built on a single cohort is available. 
Because of the large numbers of years and cohorts to make comparisons, we used only 
crude single number summaries, the AUC and HLS, to evaluate discrimination and calibration, 
respectively. In practice, more extensive detailed analyses should be implemented for 
investigating the performance of risk prediction tools. The AUC and HLS statistics summarize 
the more detailed and informative graphical displays, the receiver-operating characteristic curve 
(ROC) and calibration plot. The way risk predictions are used in practice is that a risk threshold is 
chosen, above which the patient is referred to further diagnostic testing or treatment. The ROC 
specifically reports the sensitivity (number of true cancer cases correctly referred) versus 
specificity (number of non-cancer cases that are correctly not referred) for every possible choice 
of a threshold. Evaluation of risk tools should rather be based on optimizing 
specificities/sensitivities for feasible thresholds than by optimizing the threshold-free AUC 
measure. Calibration plots are preferred over the HLS as they may show more detailed patterns of 
performance which can be summarized by Cox recalibration statistics, specifically an intercept 
reflecting calibration-in-the-large, and a calibration slope reflecting the overall strength of the 
predictors in the model [41]. There are many more methods for evaluating risk prediction tools, 
including the Brier score and net-benefit curves [23]. The Brier score is an integrated measure of 
discrimination and calibration. We repeated all analyses here using the Brier score as the outcome 
and arrived at nearly the same conclusions as to those based on the AUC (Figure 3 in the 
Supplementary Appendix). Net-benefit curves are geared towards finding optimal models for 
basing clinical decisions based on thresholds – they ultimately revert to combinations of 
sensitivity, specificity and prevalence, and so are also combined measures [42]. We have chosen 
the base measures of discrimination and calibration here because they represent the two pure 
most orthogonal components of model validation [43]. 
 It has been established that shrinkage of regression coefficients or penalized regression 
may improve calibration of a risk-prediction tool by reducing the range of prediction values; see 
Chapter 13 of [23] for an overview. There are many possible options for performing shrinkage, 
but they all require an internal bootstrapping or cross-validation strategy to optimize tuning 
parameters. Shrinkage works similarly to the Bayesian method here, but estimates the amount of 
shrinkage from the data directly, instead of from a prior distribution. We tried a common method 
of shrinkage, the Lasso, which penalizes the regression by the L1-norm of the parameter vector. 
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Discrimination performance was similar to the revision and Bayesian methods, and calibration 
performance was slightly worse than that of the recalibration method. These results were not 
surprising, because shrinkage has a bigger effect on calibration than on the AUC (a robust rank-
based statistic that is difficult to move) and because our cohorts had only a small number of 
predictors (ranging from 3 to 5). However, a more thorough investigation of shrinkage methods is 
advisable for future applications. 
Even though the validation sets used to evaluate the performance of the updating methods 
were taken from the same institution and chronologically in close proximity to the training sets, 
we still encountered large variations in cancer prevalence and other patient characteristics 
between training and test sets. In order to investigate if the sudden changes in cancer prevalence 
are accompanied by similar changes to the patient characteristics, we made plots for each cohort 
where we overlay cancer prevalence over time along with the prevalence of high covariate values 
(Supplementary Appendix Figure 4). However, we could not find clear associations between the 
spikes in cancer prevalence and changes of other characteristics. These unexpected variations in 
case-mix make it even harder to automatically evaluate model performance which is a key part of 
implementing unsupervised updating of risk scores in clinical practice. Recent efforts to create a 
framework for interpreting the results of external validation in the context of clinical prediction 
models may eventually lead to improved automation of the updating process [44]. 
In conclusion, a commonly available risk tool may provide adequate discrimination, but 
tailoring a risk model with institution-specific data may improve calibration. We recommend 
further implementation of updating methods to increase the accuracy of prediction models that 
are used in clinical practice. 
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FIGURE CAPTIONS 
Figure 1. Yearly cancer rates for the five PBCG cohorts. 
Figure 2. AUCs using all past data as training and the next year as the validation year (x-axis). 
Higher values indicate better discrimination between cancer cases and control. The recalibration 
method gave identical results to the PCPTRC method. 
Figure 3. Hosmer-Lemeshow test statistics using all past data as training and the next year as the 
validation year (x-axis). Lower values indicate better fit, closer agreement between observed and 
predicted risks. Random forests are omitted since their values were so high as to fall off the 
graph. 
Supplementary Appendix Figure 1. AUCs using all past data as training set and the last three 
years as the validation set. Latest year used for training corresponds to the x-axis. Higher values 
indicate better discrimination between cancer cases and controls. 
Supplementary Appendix Figure 2. Hosmer-Lemeshow test statistics using all past data as 
training set and the last three years as the validation set. Latest year used for training corresponds 
to the x-axis. Lower values indicate better fit, closer agreement between observed and predicted 
risks. Random forests are omitted since their values were so high as to fall off the graph. 
Supplementary Appendix Figure 3. Brier Score using all past data as training and the next year 
as the validation year (x-axis). Lower values indicate better fit. 
Supplementary Appendix Figure 4. Changes of the patient characteristics over time for each 
cohort. The continuous variables PSA and age were dichotomized using the upper quartiles of 
PSA and age in the PBCG dataset. 
Supplementary Appendix Figure 5. Patient characteristics from the year before until the year 
after a drastic change in cancer prevalence. The continuous variables PSA and age were 
dichotomized using the upper quartiles of PSA and age in the PBCG dataset. 
Supplementary Appendix Figure 6. Patient Characterstics of the training and validation set for 
several years where the static PCPTRC outperformed the dynamically updated methods based on 
the Hosmer-Lemeshow statistic. The continuous variables PSA and age were dichotomized using 
the upper quartiles of PSA and age in the PBCG dataset. 
Supplementary Appendix Figure 7. Yearly Hosmer-Lemeshow test statistics across validation 
years for the static PCPTRC and the recalibration method. The 95% confidence intervals are 
generated from 200 bootstrapped samples stratified by outcome. 
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Supplementary Appendix Figure 8. Hosmer-Lemeshow test statistics (HLS) for the static 
PCPTRC and the updating methods Recalibration and Revision in the cohorts Durham VA and 
SABOR. The updating process was repeated three times: all data (left panel), only patients 
without African American origin (middle panel) and just African American patients (right panel). 
SABOR had not enough African American participants to warrant a separate analysis. For 
Durham the updating and validation process was performed bi-annually to counteract the reduced 
sample size. Lesser values of the HLS correspond to better fit.
  
22 
 
TABLE CAPTIONS 
 
Table 1. Biopsy characteristics from the five PBCG cohorts. Prostate specific antigen (PSA) 
measured in ng/ml. Risk factors used in the models for each cohort (≤ 15% missing); SABOR & 
Cleveland Clinic: PSA, age, DRE, race, prior biopsy; ProtecT: PSA, age, family history, race; 
Tyrol: PSA, age, prior biopsy, DRE; Durham VA: PSA, age, race, prior biopsy. 
Supplementary Appendix Table 1: PCPTRC formulas for prediction of cancer dependent on 
the available risk factors—this model was built from 6664 biopsies from the placebo arm of the 
Prostate Cancer Prevention Trial. Options M1 through M5 for the linear predictor M are allowed 
depending on what predictors are available. 
Supplementary Appendix Table 2: Number of biopsies performed by year in the five PBCG 
cohorts. 
Supplementary Appendix Table 3. Average AUC, range, and 95% confidence interval for the 
average AUC across all validation years for each cohort and method. The method with the 
highest AUC in each cohort is indicated in bold. 
Supplementary Appendix Table 4. Average Hosmer-Lemeshow test statistic, range, and 95% 
confidence interval for the average AUC across all validation years for each cohort and method. 
The method with the highest AUC in each cohort is indicated in bold. 
Supplementary Appendix Table 5. Parameters used for the randomForest() routine in the 
R package randomForest. We initially performed a Grid search to find a single set of 
parameters that would improve the method for all cohorts in all years. Since we couldn’t find 
such a constellation, the default values of the package were used for the article. 
 
 
